journal article·2017-08-18Open access

PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study

Abhishek K. Sah, Preeti K. Suresh, Vinod K. Verma

Abstract

The purpose of the present study was to develop loteprednol etabonate (LE) loaded poly(d,l-lactide co-glycolide) (PLGA) nanoparticles (NPs) and study their penetration profile into the excised goat cornea. In the present study, LE loaded PLGA NPs were prepared by solvent evaporation with high speed homogenization method and the penetration profile was studied using confocal laser scanning microscopy (CLSM). Rhodamine (Rd) was used as a fluorescent marker to prepare Rd-LE-PLGA-NPs. The NPs were characterized for particle size, X-ray diffraction (XRD), differential scanning calorimetry (DSC), transmission electron microscopy (TEM), drug entrapment, and permeation profile. Intense fluorescence observed across the depths of goat corneal tissue suggested an improved penetration profile of NPs. The entrapment efficiency and mean diameter of the optimized formulation (F5) were found to be 96.31 ± 1.68% and 167.6 ± 0.37 nm, respectively. These findings indicate that LE loaded PLGA NPs may serve as a potential drug carrier for ocular administration in eye disease.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

University Institute of Pharmacy, Faculty of Technology, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India;

State Drug Testing Laboratory, Food and Drugs Administration, Govt. of Chhattisgarh, Raipur, Chhattisgarh, India

References (27)

Show source-provided references
1. 10.1248/yakushi.126.136910.1248/yakushi.126.1369 ↗
2. Aukunuru JV · Drug Del Technol · 2002 · 2 · 50
3. 10.1016/0378-5173(94)90179-110.1016/0378-5173(94)90179-1 ↗
4. 10.1016/j.nano.2009.09.00210.1016/j.nano.2009.09.002 ↗
5. 10.1016/j.nano.2009.10.00410.1016/j.nano.2009.10.004 ↗
6. 10.1016/j.colsurfb.2010.09.01010.1016/j.colsurfb.2010.09.010 ↗
7. 10.1016/j.colsurfb.2012.10.05610.1016/j.colsurfb.2012.10.056 ↗
8. 10.1016/j.ijbiomac.2011.11.01710.1016/j.ijbiomac.2011.11.017 ↗
9. 10.1002/jbm.a.3065410.1002/jbm.a.30654 ↗
10. 10.1016/j.ijpharm.2004.11.02710.1016/j.ijpharm.2004.11.027 ↗
11. 10.4103/2231-4040.12141610.4103/2231-4040.121416 ↗
12. 10.1023/A:101427691736310.1023/A:1014276917363 ↗
13. 10.1002/jps.2423110.1002/jps.24231 ↗
14. 10.1016/S0928-0987(02)00057-X10.1016/S0928-0987(02)00057-X ↗
15. 10.1023/B:PHAM.0000022411.47059.7610.1023/B:PHAM.0000022411.47059.76 ↗
16. Qaddoumi MG · Mol Vision · 2003 · 9 · 559
17. 10.3109/02713683.2010.50886710.3109/02713683.2010.508867 ↗
18. 10.1208/pt07035710.1208/pt070357 ↗
19. Sah AK · Asian J Pharm Clin Res · 2011 · 4 · 140
20. 10.1155/2014/68939110.1155/2014/689391 ↗
21. 10.2174/156720181166614011511312710.2174/1567201811666140115113127 ↗
22. 10.1016/j.ejpb.2012.12.01010.1016/j.ejpb.2012.12.010 ↗
23. 10.1016/S0168-3659(00)00339-410.1016/S0168-3659(00)00339-4 ↗
24. 10.1111/jphp.1213210.1111/jphp.12132 ↗
25. 10.1016/j.carbpol.2010.03.06510.1016/j.carbpol.2010.03.065 ↗
26. 10.1016/j.jpba.2004.06.00610.1016/j.jpba.2004.06.006 ↗
27. 10.2147/IJN.S642810.2147/IJN.S6428 ↗